Graft-Versus-Host Disease (GVHD) Clinical Trials

A listing of Graft-Versus-Host Disease (GVHD) medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 41 clinical trials
Topical Ruxolitinib for Cutaneous Chronic Graft Versus Host Disease (cGVHD)

Background About half the people who have a hematopoietic stem cell transplant using donor cells get cGVHD. This is chronic graft versus host disease. Immune cells from the donor may see the body tissues in the person as foreign and attack, causing damage. The skin is the most commonly affected …

cancer
ruxolitinib
neutrophil count
immunosuppressive agents
chronic graft versus host disease
  • 32 views
  • 17 Sep, 2021
  • 1 location
Optimizing PTCy Dose and Timing

Background Stem cell or bone marrow transplants can cure or control blood cancers. Sometimes the donor cells see the recipient s body as foreign. This can cause complications. A high dose of the drug cyclophosphamide (PTCy) can help reduce these risks. Researchers want to see if a lower dose of …

hematologic malignancy
lymphoid leukemia
chronic leukemia
white blood cell count
cyclosporine
  • 42 views
  • 12 Sep, 2021
  • 1 location
GVHD Prophylaxis With Methotrexate in Haploidentical HCT Using Posttransplant Cyclophosphamide

patients lacking a HLA-matched donor due to its prompt availability, possibly lower cost and results comparable with other donor types. Graft-versus-host disease (GVHD) is the main cause of morbidity and

mycophenolate
chronic myeloid leukemia
cyclosporine
leukemia
remission
  • 0 views
  • 23 Sep, 2021
  • 2 locations
Nonmyeloablative Peripheral Blood Mobilized Hematopoietic Precursor Cell Transplantation for Sickle Cell Disease and Beta-thalassemia in People With Higher Risk of Transplant Failure

Background Some sickle cell disease or beta-thalassemia can be cured with transplant. Researchers want to test a variation of transplant that uses low dose radiation and a combination of immunosuppressive drugs. They want to know if it helps a body to better accept donor stem cells. Objectives To see if …

apheresis
mobilized
arteriopathy
thal
cyclophosphamide
  • 43 views
  • 17 Sep, 2021
  • 1 location
RGI-2001 for the Prevention of Acute Graft-vs-Host Disease in Subjects Following Allogeneic Hematopoietic Stem Cell Transplantation

This Phase II open label study will evaluate the safety and efficacy of repeat doses of RGI-2001 in combination with standard of care treatment for the prevention of acute graft-vs-host-disease (aGvHD) in subjects following Allogeneic Hematopoietic Stem Cell Transplantation (alloHSCT). These subjects will be compared to contemporary controls.

hematologic malignancy
allogeneic hematopoietic stem cell transplant
lymphoid leukemia
acute graft-versus-host disease
leukemia
  • 5 views
  • 26 Sep, 2021
  • 7 locations
Conditioning SCID Infants Diagnosed Early

-versus-host disease (GVHD), the stem cells will have most, but not all, of the T cells removed, using a newer, experimental approach of a well-established technology. Once the stem cell transplant is

  • 0 views
  • 23 Sep, 2021
  • 20 locations
Medical Home Care for Hematopoietic Stem Cell Transplantation Phase 2

during the pancytopenic phase; despite these measures, infectious complications and graft versus host disease (GVHD) remained common and lead to significant morbidity and mortality after HCT. Currently

cancer
graft versus host disease
cell transplantation
  • 6 views
  • 24 Sep, 2021
  • 1 location
Study of Palifermin (Kepivance) in Persons Undergoing Unrelated Donor Allogeneic Hematopoietic Cell Transplantation

destroys the donor s cells. Or donor immune cells attack the recipient s tissues, called graft-versus-host disease (GVHD). This is less likely when the recipient and donor have similar human leukocyte

hematologic malignancy
filgrastim
prednisone
immunofixation
tacrolimus
  • 23 views
  • 26 Sep, 2021
  • 2 locations
Phase I/II Study to Reduce Post-transplantation Cyclophosphamide Dosing for Older or Unfit Patients Undergoing Bone Marrow Transplantation for Hematologic Malignancies

phenotypes. Post-transplantation cyclophosphamide (PTCy) reduces rates of severe acute and chronic graft-versus-host disease (GVHD) after allogeneic hematopoietic cell transplantation (HCT) and

hematologic malignancy
granulocyte colony stimulating factor
mycophenolate
total body irradiation
fludarabine
  • 0 views
  • 26 Sep, 2021
  • 2 locations
RIC Regimen for Low- and Intermediate-risk MDS Receiving Haplo-HSCT

This study aimed to evaluate the efficacy of reduced intensity conditioning (RIC) regimen in low- and intermediate-risk myelodysplastic syndrome (MDS) patients who receive haploidentical hematopoietic stem cell transplantation (haplo-HSCT). Haplo-HSCT is an effective treatment option for MDS patients who did not have identical sibling donor (ISD) or unrelated donor (URD). …

thymoglobulin
cytarabine
fludarabine
antithymocyte globulin
transplant conditioning
  • 8 views
  • 24 Sep, 2021
  • 1 location